NASDAQ · CSTE

Caesarstone Ltd.

$2.09 -$0.11 (-5.00%) 1D Market open

Key Metrics

$76.07M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$47.07M
Beta · 1Y 1.28
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 20
    The stock moved +31.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 20
  • Mar 13
    From its Feb 3 high, the share price fell 75%.

    Peak close $2.48 on Feb 3; trough close $0.62 on Mar 13. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -75%
  • Mar 4
    The stock moved -27.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$76.07M
Enterprise value$44.55M
Shares outstanding34.6M
52-wk range$0.56 – $2.62
Avg volume · 20D156.6K
Net cash $31.52M
Book value / share$4.03
ExchangeNASDAQ
About Caesarstone Ltd.
IPO dateMar 22, 2012
Employees1266

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio1.83
Quick ratio1.15
Debt / equity0.19
Debt / EBITDA
Net cash $31.52M
Working capital$114.91M

Cash Flow · TTM

Operating CF −$38.03M
Capex −$9.04M
Free cash flow −$47.07M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings